JNJ Stock Surges on Oncology Wins Despite Lower Trading Volume

# Johnson & Johnson Stock Analysis: JNJ Trading Update, FDA Approval & Analyst Price Targets | Healthcare Stock Podcast **Episode Description:** Dive into the latest Johnson & Johnson (JNJ) stock analysis as shares trade at $242.79, down 0.38% from the previous close. This comprehensive episode covers JNJ's impressive performance with 18% year-to-date gains and 57% growth over the past year, reaching a massive $587 billion market cap. Discover key catalysts driving the healthcare giant, including FDA approval of TECVAYLI plus DARZALEX FASPRO for multiple myeloma treatment, which strengthens Johnson & Johnson's oncology portfolio. Learn about the $65 million Tracleer antitrust settlement and what it means for investors. Get the latest analyst insights with Citigroup raising its price target to $274 (12.94% upside potential) and maintaining a buy rating. We break down consensus targets, ratings from TD Cowen and Goldman Sachs, plus notable changes in short interest (up 20.8%) and insider selling activity. With 5.3% operational growth projecting $94.2 billion in 2025 revenue, a 2.1% dividend yield, and strong performance against healthcare peers, discover whether JNJ stock deserves a place in your portfolio. **Keywords:** Johnson & Johnson stock, JNJ stock analysis, healthcare stocks, pharmaceutical stocks, FDA approval, analyst price targets, dividend stocks, stock market podcast, investment analysis *A Quiet Please Production | Subscribe for daily stock market insights* For more http://www.quietplease.ai Stock up on these deals https://amzn.to/3QFpYIX This content was created in partnership and with the help of Artificial Intelligence AI.